I had an early appointment at the hospital today. It’s a week earlier than normal as we of to Germany next week. I was told that I would be seeing Dr Minawi and as I sat in her treatment room waiting for her I was then told to move to Prof Harris’ room. It seems he wanted to see me?! Any who in he trots as jovial as ever and said that I looked really well. I told him I had a cold. He didn’t seem at all concerned and said that the chemo wouldn’t affect me whilst having a cold. I told him I wasn’t concerned. I didn’t mean for it to sound quite so blunt but I meant it. I am not concerned.
He said that he has been looking sat my blood tests and they look great. He said that my haemoglobin levels look fine and that you wouldn’t even know I am on chemo! Wow! I am well chuffed with that. That’s’ so encouraging. Right now I feel just snotty and rough round the edges but I am sure by the weekend I should be feeling better.
I am back at the hospital Thursday or Friday to have another blood test and to pick up my next course of chemo. That will be round seven. Prof Harris knows my scan is all booked and it seems I have a month till I get the results.
Some really exciting news… Pete came across some more research yesterday that sounds just unreal! Here is an excerpt of the article;
….’fortunately, better drug therapies may be on the horizon. UCLA researchers and collaborators led by Dean Ho, a professor at the UCLA School of Dentistry and co-director of the school’s Jane and Jerry Weintraub Center for Reconstructive Biotechnology, have developed a potentially more effective treatment for TNBC that uses nanoscale, diamond-like particles called nanodiamonds.
Nanodiamonds are between 4 and 6 nanometers in diameter and are shaped like tiny soccer balls. Byproducts of conventional mining and refining operations, the particles can form clusters following drug binding and have the ability to precisely deliver cancer drugs to tumours, significantly improving the drugs’ desired effect. In the UCLA study, the nanodiamond delivery system has been able to home in on tumour masses in mice with triple negative breast cancer.
Findings from the study are published online April 15 in the peer-reviewed journal Advanced Materials.
“This study demonstrates the versatility of the nanodiamond as a targeted drug-delivery agent to a tumour site,” said Ho, who is also a member of the California NanoSystems Institute at UCLA, UCLA’s Jonsson Comprehensive Cancer Centre and the UCLA Department of Bioengineering. “The agent we’ve developed reduces the toxic side effects that are associated with treatment and mediates significant reductions in tumour size.”
The team combined several important cancer-fighting components on the nanodiamond surface, including Epirubicin, a highly toxic but widely used chemotherapy drug that is often administered in combination with other cancer drugs. The new compound was then bound to a cell-membrane material coated with antibodies that were targeted toward the epidermal growth factor receptor, which is highly concentrated on the surfaces of TNBC cells. The resulting agent is a drug-delivery system called a nanodiamond-lipid hybrid compound, or NDLP.
When tested on mice, the agent was shown to notably decrease tumor growth and eliminate the devastating side effects of cancer treatment.
Because of its toxicity, Epirubicin, when administered alone can cause serious side effects, such as heart failure and reduced white blood cell count, and it has been linked to an increased risk for leukaemia. In the study, all of the mice that were given Epirubicin alone died well before the completion of the study. But all the mice given Epirubicin through the targeted NDLPs survived the treatment, and some of the tumours even regressed until they were no longer visible.
“Triple-negative breast cancer is often very aggressive and hard to treat, making aggressive chemotherapy a requirement,” said Dr. Edward K. Chow, co-first author of the study and an assistant professor at the Cancer Science Institute of Singapore. “The targeting and therapeutic efficiency of the nanodiamond-lipid agents were quite remarkable. The simultaneous tumor regression and improved drug tolerance are promising indicators for the continued development of the nanodiamonds toward clinical translation.”
The research team is now studying the efficacy and safety of the NDLPs in larger animals. Additional research objectives include determining whether nanodiamonds can enhance the tolerance of a wide spectrum of highly toxic drug compounds, which may improve current treatment options and outcomes. These discoveries will serve as precursors for human trials, the researchers said.
“The nanodiamond-lipid hybrid developed in this study is a modular platform,” said Laura Moore, a graduate student in Ho’s laboratory and a co-first author of the study. “Therefore, we can easily bind a wide spectrum of targeting antibodies and drug compounds to address several diseases.”
Dr. No-Hee Park, dean of the UCLA School of Dentistry, noted that the research will provide a foundation for future clinical applications.
“This pioneering study conducted by Dean Ho and his team provides a better understanding of the capabilities of the nanodiamond material to address several diseases,” Park said. “Their work is of paramount importance.”
There is more exciting news featured on my forum about another potential cure for triple negative breast canSer. Take a look:
This news is amazing. It is abundantly clear that there isn’t going to one thing that cures canSer. It will never be cured with on drug alone. It seems everything should be complementary and will work in synergy together. But how encouraging is this news?
Back home from the hospital and I am working today again… Big smiles and lots of feel good feelings! Although, in order not to spread my germs I will be wearing a mask over my nose and mouth!